deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT02959554

Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control (NIVOSWITCH)

A Randomized Phase II Study With NIVOlumab or Continuation of Therapy as an Early SWITCH Approach in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) and Disease Control After 3 Months of Treatment With a Tyrosine Kinase Inhibitor

Sponsor: AIO-Studien-gGmbH

Conditions Metastatic Renal Cell Carcinoma
Interventions Nivolumab Pazopanib Sunitinib
Updated 12 times since 2017 Last updated: Sep 7, 2021 Started: Dec 31, 2016 Primary completion: Aug 31, 2020 Completion: Jan 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from AIO-Studien-gGmbH

See all terminations from AIO-Studien-gGmbH

Other Metastatic Renal Cell Carcinoma trials with similar outcome

Browse all Metastatic Renal Cell Carcinoma trials

This PHASE2 trial investigates Metastatic Renal Cell Carcinoma and is currently terminated or withdrawn. AIO-Studien-gGmbH leads this study, which shows 12 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotRecruiting~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotRecruiting~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshotRecruiting~Nov 2018 – ~Feb 2020 · 15 months · monthly snapshotActive Not Recruiting~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~May 2021 · 4 months · monthly snapshotActive Not Recruiting~May 2021 – ~Oct 2021 · 5 months · monthly snapshotActive Not Recruiting~Oct 2021 – ~Jul 2024 · 33 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Oct 2021 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  5. May 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2018 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  5. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  6. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AIO-Studien-gGmbH
  • Bristol-Myers Squibb
Data source: AIO-Studien-gGmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations